For Healthcare Professionals

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy


About the study

The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

  1. Age ≤ 6 weeks at first dose.
  2. Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound heterozygous mutation.
  3. Genetic documentation of 2 or 3 copies of survival motor neuron 2 (SMN2).
  4. Ulnar compound muscle action potential (CMAP) ≥ 1 mV at Baseline.
  5. Gestational age of 37 to 42 weeks for singleton births; gestational age of 34 to 42 weeks for twins.
  6. Meet additional study related criteria.


Key Exclusion Criteria:

  1. Hypoxemia (oxygen saturation <96% awake or asleep without any supplemental oxygen or respiratory support).
  2. Any clinical signs or symptoms at Screening or immediately prior to the first dosing (Day 1) that are, in the opinion of the Investigator, strongly suggestive of SMA.
  3. Clinically significant abnormalities in hematology or clinical chemistry parameters.
  4. Treatment with an investigational drug given for the treatment of SMA biological agent, or device. Any history of gene therapy, prior antisense oligonucleotide (ASO) treatment, or cell transplantation.
  5. Meet additional study related criteria.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Spinal Muscular Atrophy

Age (in years)

< 6


Phase 2

Participants needed


Est. Completion Date

Jan 27, 2025

Treatment type



Biogen identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.